menu
    • menu

    Company profile for Constant Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Constant Therapeutics LLC is a clinical stage company developing Mas receptor agonists for treatment of COVID-19, CNS, and rare disorders. It’s lead clinical programs are in COVID-19, chronic stroke recovery, epidermolysis bullosa and cardiomyopathy associated with Duchenne Muscular Dystrophy. Constant was recently formed by combining the assets of TarixCVM LLC and Tarix Orphan LLC.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Constant TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Boston, MA, United States
    Telephone
    Telephone
    +1-617-245-0289
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.constanttherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Constant Therapeutics Announces First Patient Dosed in Phase 2 Trial of TXA127
    Constant Therapeutics Announces First Patient Dosed in Phase 2 Trial of TXA127

    09 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/constant-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-trial-of-txa127-in-ischemic-stroke-recovery-302030169.html

    PR NEWSWIRE
    09 Jan 2024
    Share Share
    Constant Tx TXA127 To Enter NIH-Funded Clinical Trial At 60 Sites Around The US
    Constant Tx TXA127 To Enter NIH-Funded Clinical Trial At 60 Sites Around The US

    12 May 2021

    // BIOSPACE

    https://www.biospace.com/article/releases/constant-therapeutics-txa127-for-covid-19-to-enter-nih-funded-clinical-trial-at-60-sites-around-the-u-s-/

    BIOSPACE
    12 May 2021
    Share Share
    Constant announces start of Phase 2 trial of peptide drug TXA127 for COVID-19
    Constant announces start of Phase 2 trial of peptide drug TXA127 for COVID-19

    29 Jul 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/constant-therapeutics-announces-start-of-phase-2-trial-of-peptide-drug-txa127-for-covid-19-301101668.html

    PRNEWSWIRE
    29 Jul 2020
    Share Share
    Constant Therapeutics announces start of Phase 2 trial of peptide drug TXA127
    Constant Therapeutics announces start of Phase 2 trial of peptide drug TXA127

    29 Jul 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/constant-therapeutics-announces-start-of-phase-2-trial-of-peptide-drug-txa127-for-covid-19-301101668.html

    PRNEWSWIRE
    29 Jul 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search